Triplet cytotoxic chemotherapy with gemcitabine, 5-fluorouracil and cisplatin for advanced pancreatic cancer

Sohn, Byeong Seok; Yuh, Young Jin; Song, Hong Suk; Kim, Bong‐Seog; Lee, Kyung Hee; Jang, Jae Seong; Kim, Sung Rok

doi:10.3892/ol.2015.3347

Cited by 2 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The further evidence showed that the short‐term efficacy of Gemcitabine + Cisplatin, Gemcitabine + Capecitabine were relatively better compared to other chemotherapy regimens. A combination of gemcitabine and cisplatin conceived an ORR of 11–26.4%, which was better than gemcitabine alone, and the median survival time was 7.1–8.2 months [Sohn et al, ]. Gemcitabine plus capecitabine may be considered as a standard first‐line treatment option for advanced PC, which showed a remarkable trend in improving the OS in the treatment of PC [Lee and Park, ].…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Toxicity of Different Chemotherapy Regimens in the Treatment of Advanced or Metastatic Pancreatic Cancer: A Network Meta‐Analysis

Liu

Zhao

2017

J of Cellular Biochemistry

View full text Add to dashboard Cite

Objective A network meta-analysis was conducted to compare the efficacy and toxicity of different chemotherapy regimens in treating advanced or metastatic pancreatic cancer (PC). PubMed, Cochrane Library and EMBASE databases from inception to June 2016 were searched. A combination of direct and indirect evidences was referred to for calculating the weighted mean difference (WMD) or the odds ratio (OR) and to establish surface under the cumulative ranking (SUCRA) curves, so as to evaluate the efficacy and toxicity of different chemotherapy regimens in treating advanced or metastatic PC. Twenty randomized controlled trials were enrolled. Twelve chemotherapy regimens included, Gemcitabine þ Oxaliplatin, and Gemcitabine þ Pemetrexed. Higher overall response rate (ORR) was observed in patients treated with the gemcitabine þ S-1 and FOLFIRINO regimens. Thrombocytopenia reduced in patients treated with the S-1 regimen. The Gemcitabine þ S-1 and FOLFIRINO regimens had better short-and long-term efficacies than the other regimens; S-1 regimen had the lowest hematologic toxicity, while Gemcitabine þ Nab-paclitaxel, FOLFIRINOX, and Gemcitabine þ Pemetrexed regimens had higher incidence of non-hematologic toxicity among twelve chemotherapy regimens. The efficacy of Gemcitabine þ S-1 and FOLFIRINOX regimens may be better in treating patients with advanced or metastatic pancreatic cancer, while FOLFIRINOX and Gemcitabine þ Pemetrexed regimens may have relatively higher incidence of toxicity than other regimens.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy and Toxicity of Different Chemotherapy Regimens in the Treatment of Advanced or Metastatic Pancreatic Cancer: A Network Meta‐Analysis

Liu

Zhao

2017

J of Cellular Biochemistry

View full text Add to dashboard Cite

show abstract

“…We evaluated the effect of TRPV6 expression on the resistance of Panc-1 cells to three chemotherapeutic drugs: gemcitabine, cisplatin, and 5-FU. These drugs are commonly used in the treatment of pancreatic cancer, but often fail to achieve satisfactory outcomes due to the development of drug resistance [31][32][33][34]. We found that TRPV6 knockdown sensitizes Panc-1 cells to 5-FU treatment.…”

Section: Discussionmentioning

confidence: 78%

TRPV6 Channel Is Involved in Pancreatic Ductal Adenocarcinoma Aggressiveness and Resistance to Chemotherapeutics

Mesquita,

Haustrate,

Mihalache

et al. 2023

Cancers

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) stands as a highly aggressive and lethal cancer, characterized by a grim prognosis and scarce treatment alternatives. Within this context, TRPV6, a calcium-permeable channel, emerges as a noteworthy candidate due to its overexpression in various cancers, capable of influencing the cell behavior in different cancer entities. Nonetheless, the exact expression pattern and functional significance of TRPV6 in the context of PDAC remains enigmatic. This study scrutinizes the expression of TRPV6 in tissue specimens obtained from 46 PDAC patients across distinct stages and grades. We manipulated TRPV6 expression (knockdown, overexpression) in the human PDAC cell lines Panc-1 and Capan-1. Subsequently, we analyzed its impact on multiple facets, encompassing Ca2+ influx, proliferation, apoptosis, migration, chemoresistance, and tumor growth, both in vitro and in vivo. Notably, the data indicate a direct correlation between TRPV6 expression levels, tumor stage, and grade, establishing a link between TRPV6 and PDAC proliferation in tissue samples. Decreasing TRPV6 expression via knockdown hampered Ca2+ influx, resulting in diminished proliferation and viability in both cell lines, and cell cycle progression in Panc-1. The knockdown simultaneously led to an increase in apoptotic rates and increased the susceptibility of cells to 5-FU and gemcitabine treatments. Moreover, it accelerated migration and promoted collective movement among Panc-1 cells. Conversely, TRPV6 overexpression yielded opposing outcomes in terms of proliferation in Panc-1 and Capan-1, and the migration of Panc-1 cells. Intriguingly, both TRPV6 knockdown and overexpression diminished the process of tumor formation in vivo. This intricate interplay suggests that PDAC aggressiveness relies on a fine-tuned TRPV6 expression, raising its profile as a putative therapeutic target.

show abstract

Triplet cytotoxic chemotherapy with gemcitabine, 5-fluorouracil and cisplatin for advanced pancreatic cancer

Cited by 2 publications

References 35 publications

Efficacy and Toxicity of Different Chemotherapy Regimens in the Treatment of Advanced or Metastatic Pancreatic Cancer: A Network Meta‐Analysis

Efficacy and Toxicity of Different Chemotherapy Regimens in the Treatment of Advanced or Metastatic Pancreatic Cancer: A Network Meta‐Analysis

TRPV6 Channel Is Involved in Pancreatic Ductal Adenocarcinoma Aggressiveness and Resistance to Chemotherapeutics

Contact Info

Product

Resources

About